Viatris Inc.

NASDAQ:VTRS

Drug Manufacturers - Specialty & Generic

Healthcare
$20.28 -2.29%

-$0.36 today

Market cap
$23.25B
Beta
0.90
P/E (TTM)
-59.9
EPS (TTM)
-$0.26
Dividend yield
3.12%
52W Low $8.63High $17.53

Volume 13.21M

Average 10.58M

VTRS Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Viatris Inc.NASDAQ: VTRS

Net Receivables · Q2 FY2026 · quarter ended Jun 2026

Net receivables rises 2.0% from a year ago

Net receivables stood at $3.67B at the end of Q2 FY2026, up 2.0% from a year earlier and down 1.9% from the prior quarter. Over 3 fiscal years it compounded at -6.9% a year.

Context

  • Net receivables amounted to 10.5% of total assets at the end of Q2 FY2026, up 1.1 pp from a year earlier.
  • Net receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +2.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.67B-1.9% QoQ
Last fiscal yearDec 2025
$3.35B-5.0% YoY
Year agoJun 2025
$3.6B+2.0% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.0%——
1 year-5.0%——
3-year CAGR-6.9%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
3.35B USD
Year-over-year change
-5.0%
4-year CAGR
-5.9%

Net Receivables vs competitors

How VTRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +2.0% is the 6th highest of 10, against a peer median of +2.4%.
  • Net receivables amounts to 10.5% of total assets for VTRS, versus a peer median of 10.4%.
VTRS Competitors
Net Receivables for VTRS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RDYDr. Reddy's Laboratories LimitedSep 2026₹101.84B INR-15.7%+6.0%17.7%
VTRSViatris Inc.Jun 2026$3.67B USD+2.0%-6.9%10.5%
TEVATeva Pharmaceutical Industries LimitedJun 2026$3.49B USD-2.0%+0.1%8.8%
BHCBausch Health Companies Inc.Jun 2026$2.26B USD+2.4%+9.4%9.1%
HLNHaleon plcDec 2025£2.12B GBP+11.3%+12.5%6.5%
OGNOrganon & Co.Sep 2026$1.48B USD-2.7%-3.7%11.0%
AMRXAmneal Pharmaceuticals, Inc.Jun 2026$1.02B USD+20.2%+8.2%27.0%
ALKSAlkermes plcSep 2026$459.09M USD+29.3%+4.0%10.4%
ANIPANI Pharmaceuticals, Inc.Mar 2026$255.43M USD+15.9%+19.3%18.0%
AMPHAmphastar Pharmaceuticals, Inc.Mar 2026$147.85M USD+1.7%+17.4%9.0%
Peer median (excluding VTRS) —+2.4%+8.2%10.4%

Competitors are the stored peer set for VTRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents701.2M1.26B991.9M734.8M1.35B
Short-term Investments233.8M212.6M192.5M355.1M106.4M
Net Receivables4.27B4.14B4.04B3.52B3.35B
Inventory3.98B3.52B3.47B3.85B4B
Other Current Assets1.47B1.31B4.13B913.8M194.8M
Total Current Assets10.9B10.64B12.98B9.52B9.22B
Property, Plant & Equipment (Net)3.48B3.28B3.01B2.92B2.89B
Goodwill12.11B10.43B9.87B9.13B6.75B
Intangible Assets26.13B22.61B19.18B17.07B15.1B
Long-term Investments81.4M1.09B1.14B1.35B815M
Tax Assets1.33B925.9M692.9M753M1.06B
Other Non-current Assets798.5M1.05B821.1M754M1.35B
Total Non-current Assets43.94B39.39B34.71B31.98B27.97B
Total Assets54.84B50.02B47.69B41.5B37.19B
Account Payables1.06B1.16B1.38B1.36B1.29B
Short-term Debt3.35B1.25B1.93B600K2.04B
Tax Payables236.9M279.6M226.8M192.7M0
Deferred Revenue00000
Other Current Liabilities1.41B1.24B1.41B1.34B2.88B
Total Current Liabilities9.88B6.75B7.78B5.78B7.09B
Long-term Debt19.72B18.02B16.19B14.04B12.48B
Deferred Tax Liabilities2.82B2.43B1.74B1.11B892M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.73B1.58B1.35B1.76B1.84B
Total Non-current Liabilities24.47B22.2B19.44B17.09B15.39B
Total Liabilities34.35B28.95B27.22B22.87B22.48B
Common Stock12.1M12.1M12.2M12.3M12.5M
Retained Earnings3.69B5.18B4.64B3.42B(388.3M)
Accumulated OCI(1.74B)(2.76B)(2.75B)(3.21B)(2.71B)
Other Stockholders Equity00000
Minority Interest00000
Total Equity20.49B21.07B20.47B18.64B14.71B
Total Debt23.36B19.53B18.37B14.31B14.7B
Net Debt22.66B18.27B17.38B13.57B13.35B

Viatris Inc.

NASDAQ:VTRS

Intrinsic Alpha fair value

Locked

Current Price

$20.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.